Laboratory Corp. of America Holdings (NYSE:LH) Shares Acquired by Weybosset Research & Management LLC

Weybosset Research & Management LLC lifted its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 0.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,325 shares of the medical research company’s stock after buying an additional 85 shares during the period. Laboratory Corp. of America makes up approximately 3.8% of Weybosset Research & Management LLC’s holdings, making the stock its 14th largest position. Weybosset Research & Management LLC’s holdings in Laboratory Corp. of America were worth $6,607,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealthfront Advisers LLC raised its holdings in Laboratory Corp. of America by 3.1% during the third quarter. Wealthfront Advisers LLC now owns 2,054 shares of the medical research company’s stock worth $345,000 after purchasing an additional 62 shares in the last quarter. DNB Asset Management AS increased its holdings in Laboratory Corp. of America by 0.6% in the third quarter. DNB Asset Management AS now owns 10,579 shares of the medical research company’s stock valued at $1,777,000 after buying an additional 64 shares in the last quarter. Squar Milner Financial Services LLC increased its holdings in Laboratory Corp. of America by 6.4% in the second quarter. Squar Milner Financial Services LLC now owns 1,090 shares of the medical research company’s stock valued at $188,000 after buying an additional 66 shares in the last quarter. Hartford Investment Management Co. increased its holdings in Laboratory Corp. of America by 0.3% in the second quarter. Hartford Investment Management Co. now owns 20,629 shares of the medical research company’s stock valued at $3,567,000 after buying an additional 67 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in Laboratory Corp. of America by 4.1% in the second quarter. Diversified Trust Co now owns 1,763 shares of the medical research company’s stock valued at $305,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 90.37% of the company’s stock.

A number of research analysts have issued reports on the stock. Barclays set a $200.00 target price on shares of Laboratory Corp. of America and gave the company a “buy” rating in a report on Monday, July 15th. Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating and set a $172.00 target price for the company in a report on Wednesday, October 9th. Morgan Stanley increased their target price on shares of Laboratory Corp. of America from $190.00 to $201.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. KeyCorp increased their target price on shares of Laboratory Corp. of America from $172.00 to $192.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Finally, UBS Group dropped their target price on shares of Laboratory Corp. of America from $204.00 to $200.00 and set a “buy” rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Laboratory Corp. of America presently has an average rating of “Buy” and an average price target of $184.91.

In related news, Director Kerrii B. Anderson sold 2,600 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $171.85, for a total transaction of $446,810.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director R Sanders Williams sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $162.91, for a total transaction of $81,455.00. Following the sale, the director now owns 6,886 shares in the company, valued at approximately $1,121,798.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,468 shares of company stock worth $1,946,168. 0.74% of the stock is owned by company insiders.

Shares of LH traded up $2.22 during mid-day trading on Tuesday, reaching $170.26. 142,690 shares of the company’s stock were exchanged, compared to its average volume of 563,470. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.95. The company has a 50-day simple moving average of $168.94 and a two-hundred day simple moving average of $166.26. Laboratory Corp. of America Holdings has a 52-week low of $119.38 and a 52-week high of $178.44. The company has a market cap of $16.43 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 1.87 and a beta of 1.03.

Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, July 25th. The medical research company reported $2.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.90 by $0.03. Laboratory Corp. of America had a net margin of 8.19% and a return on equity of 16.28%. The business had revenue of $2.88 billion during the quarter, compared to analysts’ expectations of $2.89 billion. During the same period last year, the company posted $2.98 EPS. The company’s revenue was up .5% on a year-over-year basis. As a group, equities research analysts predict that Laboratory Corp. of America Holdings will post 11.29 EPS for the current fiscal year.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Story: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit